Cadence Design Systems Inc (CDNS) Stock Price Today
Key Stats
- $104.18BMARKET_CAP
- -VOLUME
- TechnologySECTOR
- $416.39FIFTY_TWO_WEEK_HIGH
- $265.66FIFTY_TWO_WEEK_LOW
- -TYPICAL_HOLD_TIME
- $105.86BENTERPRISE_VALUE
- -DIVIDEND_YIELD
- -TRADING_ACTIVITY
Track Cadence Design Systems Inc (CDNS) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Cadence Design Systems Inc has traded between a low of $265.66 and a high of $416.39, highlighting its annual price range. Buy and sell Cadence Design Systems Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Cadence Design Systems Inc
Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enable system-level analysis and verification solutions. Cadence's comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers, alongside secular digitalization of various end markets, benefits EDA vendors like Cadence.
Most Recent News
Global beadlets capsule market to nearly double to $968M by 2035 with 6.85% CAGR driven by pharma and nutraceutical demand
The global beadlets capsule market is projected to grow from $467.26 million in 2025 to $968.45 million by 2035, at a compound annual growth rate of 6.85%. Growth is driven by rising demand in pharmaceutical and nutraceutical sectors, fueled by advan...

China's oil imports drop amid Middle East conflict and OPEC+ supply boost
China, the world's largest crude oil importer, has significantly reduced its oil purchases, including from Iran, amid the ongoing Middle East conflict and a strategic shift towards green energy. In May, China's crude imports fell 29% year-on-year to ...

Molecular Partners advances phase 1/2a trial of cancer-targeting Radio-DARPin MP0712 with initial data due soon
Molecular Partners is progressing its Phase 1/2a clinical trial of MP0712, a Radio-DARPin therapeutic targeting DLL3 for small cell lung and neuroendocrine cancers, with patient dosing ongoing at five US centers. Initial clinical data are expected wi...
